2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 13.091 | 59.686 | 85.353 | 113.564 | 123.293 | 133.755 | 153.975 | 164.201 | 171.617 | 162.527 |
Total Income - EUR | 13.091 | 60.152 | 86.063 | 115.513 | 123.611 | 134.215 | 154.774 | 165.079 | 172.415 | 162.530 |
Total Expenses - EUR | 14.637 | 54.401 | 77.444 | 104.452 | 109.000 | 122.328 | 138.534 | 147.275 | 161.381 | 153.089 |
Gross Profit/Loss - EUR | -1.546 | 5.751 | 8.619 | 11.061 | 14.610 | 11.888 | 16.239 | 17.804 | 11.034 | 9.441 |
Net Profit/Loss - EUR | -1.939 | 3.946 | 7.598 | 9.906 | 13.374 | 10.545 | 15.019 | 16.153 | 9.309 | 7.816 |
Employees | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Kincsőpharm S.r.l.
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 369 | 232 | 92 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Current Assets | 12.625 | 21.665 | 29.454 | 38.940 | 48.404 | 55.658 | 68.197 | 81.414 | 81.758 | 81.608 |
Inventories | 7.284 | 13.709 | 12.454 | 19.670 | 20.369 | 28.954 | 32.315 | 41.323 | 39.753 | 44.041 |
Receivables | 4.756 | 5.402 | 4.770 | 17.840 | 24.979 | 19.289 | 26.648 | 28.403 | 28.289 | 24.945 |
Cash | 585 | 2.553 | 12.230 | 1.430 | 3.057 | 7.415 | 9.235 | 11.689 | 13.716 | 12.622 |
Shareholders Funds | -1.894 | 2.036 | 9.613 | 13.596 | 24.459 | 30.094 | 39.102 | 50.132 | 53.513 | 55.673 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 14.888 | 19.861 | 19.933 | 25.344 | 23.945 | 25.564 | 29.096 | 31.283 | 28.245 | 25.935 |
Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "4773 - 4773" | |||||||||
CAEN Financial Year |
4773
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Kincsőpharm S.r.l.